SCHEMBL10069982

SCHEMBL10069982

COc1cccc(CC(O)(c2ccccc2)c2ccc(Cl)cc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.65
HTT P42858 6/20 0.65
NPSR1 Q6W5P4 6/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
GAA P10253 1/20 0.65
SIGMAR1 Q99720 1/20 0.46
CNR1 P21554 1/20 0.44
BCL2 P10415 1/20 0.44
MAOB P27338 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
XBP1 P17861 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CCR2 P41597 1/20 0.43
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9837849 0.79 LMNA (0.55) LMNAHTTNPSR1SMN1; SMN2KMT2A
SCHEMBL27977126 0.79 ALDH1A1 (0.45) LMNAHTTNPSR1SMN1; SMN2GAA
SCHEMBL8612119 0.78 LTA4H (0.53) LMNAHTTNPSR1SMN1; SMN2SIGMAR1
SCHEMBL5873436 0.76 HTT (0.53) LMNAHTTNPSR1SMN1; SMN2SIGMAR1
SCHEMBL20228977 0.75 MAOB (0.51) SIGMAR1MAOBCYP1A2CHRM3IDO1
SCHEMBL10368035 0.75 HTT (0.56) LMNAHTTNPSR1SMN1; SMN2SIGMAR1
SCHEMBL27698267 0.74 CYP1A2 (0.51) HTTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL4747589 0.73 HTT (0.53) LMNAHTTNPSR1SMN1; SMN2SIGMAR1
SCHEMBL8325279 0.73 TAAR1 (0.53) SIGMAR1MAOBCYP1A2CHRM3IDO1
SCHEMBL30183964 0.73 TAAR1 (0.53) SIGMAR1MAOBCYP1A2CHRM3IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 US disclosed
US-9273070-B2 Organozinc complexes and processes for making and using the same KNOCHEL PAUL (DE) 2016-03-01 US disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 US disclosed
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIAN-UNIVERSITAT MUNCHEN (DE) 2014-01-30 US disclosed
WO-2012085168-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031545-A1 ORGANOZINC COMPLEXES AND PROCESSES FOR MAKING AND USING THE SAME ODC1, AOC1, ADH1C LMNA 3145/4885HTT 3830/4885NPSR1 3271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.